Germany imported 201,094 kg of medical cannabis in 2025. Canadian producers supplied 93,006 kg of that, roughly 46 per cent, and in the first quarter of 2026 Canada's share climbed to 53 per cent. On 8 June 2026, the Hessian State Office for Health and Care published a guidance document that calls into question how most of that flower reaches German pharmacies.
GMP washing is the practice of importing flower cultivated under GACP certification in a third country, then processing it at an EU-GMP facility inside Europe so the batch can be released as a medicine. The Hessian guidance treats drying under controlled conditions as a critical manufacturing step. That places drying inside the GMP rules rather than the lighter agricultural standard, which means flower released as medicine in Hesse should be dried and trimmed where it was harvested unless the producer can prove the split causes no quality loss.
For a Canadian Licensed Producer, the useful question is not whether an information sheet is binding law. It's whether your German partner can draw a clean diagram of your supply chain when the authority asks for one. Most cannot. That's the real exposure.
What the Hesse guidance actually says
The Hessian State Office for Health and Care, HLfGP, issued its Merkblatt on 8 June 2026. The document does two things at once. It classifies controlled drying as a critical manufacturing step whose parameters are critical process parameters, and it states the authority is aware of no process demonstrating that flower still legitimately classed as GACP material can be transported long distances, stored, imported and processed further without loss of quality.
Follow that logic to its end and only two readings survive. Either the flower loses its GACP status somewhere in transit and processing, or it keeps that status but nobody can prove it arrived intact. Under either reading, GMP should have applied from the moment of harvest.
Why an information sheet carries weight
A Merkblatt is guidance, not regulation, and Hesse-licensed operators are not obliged to treat it as statute. That distinction matters less than it sounds. The document sets out how one licensing authority intends to read law that already exists: Article 46(f) of Directive 2001/83/EC requires holders of a manufacturing authorisation to comply with GMP principles, and EudraLex Volume 4 supplies the detail. German legal specialists reviewing the Merkblatt have described it as a statement of the current legal position rather than a new rule, and expect other state authorities to adopt the same reading, since Germany's Länder regulators coordinate closely on medical cannabis oversight.
Guidance is not law. It is, however, the reading of the law that will be applied to your importer's next application, which amounts to the same thing commercially.
Where the GACP and GMP boundary now sits
Annex 7 of the EU GMP guide has always carried a reference table splitting herbal production between the two standards. Cultivation, harvest and initial sorting sit under GACP. Extracts and preparations onward sit under GMP. Drying has lived in the ambiguous middle, and Annex 7 does permit cutting and, in some circumstances, a primary drying step under GACP conditions. Hesse reads those permissions narrowly and pushes the boundary earlier in the process.
The timing here is not accidental. The European Medicines Agency adopted a revised GACP guideline in July 2025, effective the following month, its first major revision since 2006 and the first to address indoor and controlled-environment cultivation directly. Eleven months later, a German state authority used the reinforced framework to challenge the dominant import model. Regulators rarely revise a standard and then decline to enforce it.
| Process step | Conventional reading | Hesse's reading, June 2026 |
|---|---|---|
| Cultivation and harvest | GACP | GACP, unchanged |
| Primary drying | GACP under Annex 7 | GACP only within strict limits |
| Final drying and trimming | GACP at origin | GMP, at the harvest site |
| Microbial decontamination | Post-import treatment | Reprocessing under GMP Chapter 5 |
| Packaging and batch release | GMP in the EU | GMP, with the QP answerable for earlier steps |
Decontamination is the second exposure
Techniques that reduce microbiological load, irradiation included, are classified in the Merkblatt as reprocessing under Chapter 5, section 5.67 of the EU GMP guide. Reprocessing is permitted in exceptional cases, following a documented risk assessment. Where an operator applies the treatment routinely across batches, the authority's position is that it stops being an exception and must be written into the validated standard manufacturing process.
The document also points to Category B of European Pharmacopoeia section 5.1.8 as the applicable microbiological limit. Specialists have already flagged that 5.1.8 addresses herbal products for oral use, so applying those limits to inhaled flower needs a written justification that most operators have never produced. If you decontaminate every batch and still call it an exception, that is not a compliance position. It's an open finding waiting for an inspector to write it down.
What German importers will ask Canadian LPs for
The operative requirement sits on page three of the Merkblatt. Every application submitted to the authority must arrive with a diagram showing, step by step, how the product was made. Where the diagram raises doubts, the authority may request further documentation validating transport and storage conditions.
The four-point supply chain diagram
Each process step in your chain has to be traceable to four specific answers:
- The facility where the step physically happened
- The supplier or contractor who performed it
- The conditions it was carried out under, GACP or GMP
- The evidence that the conditions were maintained, including transport and storage between sites
Responsibility for that diagram does not stop at the Canadian border. Under section 14 of Germany's Medicines Act, the Qualified Person who releases each batch for sale carries the accountability, whether or not GMP applied in the country where the step took place. Your importer's QP is signing for your drying room.
Most Canadian LPs can name the facility and the supplier without difficulty. Where they stall is the third and fourth columns. Condition-level evidence for drying means chamber temperature and humidity records, the validation data behind those parameters, deviation logs, and proof that the material never left the site between harvest and final trim. Producers who split drying across a partner site, or who ship semi-dried material for finishing, generally cannot produce that record at all.
Berlin's LAGeSo issued a statement of non-compliance to a Canadian operator in September 2025, and among the major findings was the purchase of dried cannabis flower from non-GMP facilities. Nine months later, Hesse published the Merkblatt. Two state authorities, one underlying objection. If your flower is dried or trimmed anywhere other than the site where it was harvested, treat that chain as a liability rather than a logistics choice.
What this means for Canadian export strategy
The larger operators have already moved, and their moves point in two directions. Tilray launched ARX in June 2026, a brand cultivated inside Germany at its Neumünster facility, taking the cross-border question off the table entirely. Aurora bought Safari Flower Company in April 2026 and secured a three-year EU-GMP certification for that Niagara, Ontario site in July 2026, pulling the manufacturing standard upstream to the Canadian growing site. Rubicon Organics certified GACP at its Cascadia facility in May 2026, consolidating certified cultivation at home.
Only one of those strategies is realistic for a mid-sized Canadian LP. Building or buying EU cultivation is a capital decision measured in years. Bringing quality systems up to the standard the importing authority expects, at the site where the flower is already grown and dried, is an operational one measured in audit cycles.
Single-site producers have the simpler diagram
The structural advantage in this reading belongs to producers whose flower never moves. A facility that cultivates, dries, hand-trims and packages under one roof has fewer boxes on the diagram, fewer transport legs to validate, and no third-party finishing step to explain. That was a quality argument before June 2026. It is a documentation argument now.
AlphaLeaf operates as a Health Canada Licensed Producer in Montreal, cultivating, drying and hand-trimming indoor flower from refined genetics at a single site, with ISO/IEC 17025 batch testing and full traceability behind every lot. Export authorisation under the Cannabis Act covers the shipment. The single-site record is what supports the supply chain diagram a German importer's Qualified Person now has to defend.
If you're preparing for a German tender this year, start with the diagram rather than the pitch deck. Map every step, name every site, and find the gaps before an authority does. Our guide to Canadian export requirements for Germany covers the permit sequence, and the GACP certification checklist covers what buyers verify at the cultivation stage. For the commercial context, our overview of the German medical cannabis market for Canadian LPs sets out where the volume is going.
Documentation is now the product specification. Buyers are auditing supply chains, not just certificates of analysis. To review AlphaLeaf's single-site drying and trim records for a German or EU programme, contact our export team. The paperwork travels with the flower.
Frequently Asked Questions
What is GMP washing in the medical cannabis trade?
GMP washing describes importing cannabis flower grown under GACP certification in a third country and processing it at an EU-GMP certified facility inside Europe so the batch can be released as a medicine. Hesse's June 2026 guidance challenges the model, arguing that drying is a GMP manufacturing step and cannot be retrospectively covered by processing after import.
Does the Hessian guidance apply outside Hesse?
It applies directly only to operators licensed in Hesse. German state regulators coordinate closely on medical cannabis, and legal specialists reviewing the Merkblatt expect other Länder to adopt the same interpretation. The underlying legal basis, Directive 2001/83/EC and the EU GMP guide, applies EU-wide, so competent authorities in other member states could raise equivalent challenges.
Can Canadian flower still be processed in Portugal before reaching Germany?
Portugal remains a significant processing route and shipped 55,164 kg into Germany in 2025, much of it originating elsewhere. The Hessian reading puts pressure on that route, because the question is no longer where the final GMP step happened but whether the drying and trimming steps at origin met GMP conditions and can be evidenced.
Does irradiation count as reprocessing under EU GMP?
The Hessian guidance classifies microbial reduction techniques including irradiation as reprocessing under Chapter 5, section 5.67 of the EU GMP guide. Reprocessing is allowed in exceptional cases with a documented risk assessment. Where the treatment is applied routinely across batches, it must be built into the validated standard manufacturing process instead.
What should a GACP-certified Canadian LP without EU-GMP certification do now?
Start with the supply chain diagram the authority requires: the facility, supplier, conditions and supporting evidence for every step from harvest through packaging. Producers who dry and trim on the same site as cultivation can usually evidence this quickly. Producers who split those steps across sites should expect questions from an importer's Qualified Person before a tender proceeds.
